Your browser doesn't support javascript.
loading
Natural history of acid sphingomyelinase deficiency among European patients during childhood and adolescence: A retrospective observational study.
Mengel, Eugen; Scarpa, Maurizio; Guffon, Nathalie; Jones, Simon A; Goriya, Vishal; Msihid, Jérôme; Dyevre, Valerie; Rodriguez, Carly; Gasparic, Maja; Nalysnyk, Lubomyra; Laredo, Fernando; Pulikottil-Jacob, Ruth.
Affiliation
  • Mengel E; Institute of Clinical Science for LSD, SphinCS, Hochheim, Germany.
  • Scarpa M; Regional Coordinating Center for Rare Diseases, MetabERN, Udine University Hospital, Udine, Italy.
  • Guffon N; Reference Center for Inherited Metabolic Disorders, Femme Mère Enfant Hospital, Hospices Civils de Lyon, Bron, France.
  • Jones SA; Manchester Centre for Genomic Medicine, Saint Mary's Hospital, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK.
  • Goriya V; IQVIA, Thane, Maharashtra, India.
  • Msihid J; Sanofi, Gentilly, France.
  • Dyevre V; Sanofi, Chilly-Mazarin, France.
  • Rodriguez C; IQVIA, Durham, NC, USA.
  • Gasparic M; Sanofi, Amsterdam, the Netherlands.
  • Nalysnyk L; Sanofi, Cambridge, MA, USA.
  • Laredo F; Sanofi, São Paulo, Brazil.
  • Pulikottil-Jacob R; Sanofi, Reading, UK. Electronic address: ruth.jacob@sanofi.com.
Eur J Med Genet ; 70: 104954, 2024 Aug.
Article in En | MEDLINE | ID: mdl-38852770
ABSTRACT
Acid sphingomyelinase deficiency (ASMD) is a rare, lysosomal storage disease with limited evidence on its natural history. This retrospective, medical record abstraction study aimed to characterize the natural history of ASMD (types B and A/B) during childhood and adolescence. Recruiting sites were European centers (i.e., France, Germany, Italy, and the United Kingdom) from the ASCEND-Peds trial (NCT02292654); these sites were targeted because of the rarity of ASMD and specialized care provided at these centers. The study population comprised ASMD trial patients (before exposure to treatment) and ASMD non-trial participants who were managed at the same trial sites. Overall, 18 patients were included (11 trials; 7 non-trials; median [Q1; Q3] age at ASMD diagnosis 2.5 [1.0; 4.0] years). Median follow-up duration was 10.0 years. Frequently reported medical conditions were hepatobiliary (17 [94.4%]) and blood and lymphatic system disorders (16 [88.9%]). Adenoidectomy (3 [16.7%]) was the most commonly reported surgical procedure; gastroenteritis (5 [27.8%]) was the most frequently reported infection, and epistaxis (6 [33.3%]) was the most commonly reported bleeding event. Abnormal spleen (16 [88.9%]) and liver (15 [83.3%]) size and respiratory function (8 [44.4%]) were commonly reported during physical examination. Overall, 11 (61.1%) patients were hospitalized; 6 (33.3%) patients had emergency room visits. Findings were consistent with published literature and support the current understanding of natural history of ASMD.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Sphingomyelin Phosphodiesterase Limits: Adolescent / Child / Child, preschool / Female / Humans / Infant / Male Country/Region as subject: Europa Language: En Journal: Eur J Med Genet Journal subject: GENETICA MEDICA Year: 2024 Document type: Article Affiliation country: Alemania

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Sphingomyelin Phosphodiesterase Limits: Adolescent / Child / Child, preschool / Female / Humans / Infant / Male Country/Region as subject: Europa Language: En Journal: Eur J Med Genet Journal subject: GENETICA MEDICA Year: 2024 Document type: Article Affiliation country: Alemania